Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMY9P6E)

• Drug Name: calindol Drug Info
• Synonyms: calindol; CHEMBL2092942; Clindol; GTPL719; SCHEMBL4103949; CHEMBL1801356; ZINC1494434; BDBM50404271; NCGC00344505-01

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 9882793
  CAS Number: CAS 374933-30-9
  TTD Drug ID: DMY9P6E

Molecule-Related Drug Atlas

Drug(s) Targeting G-protein coupled receptor GPCR33 (GPRC6A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-citrulline	DMT4K0Z	Acute lung injury	NB32.3	Phase 3	[4]
L-ornithine	DMHKGCM	Discovery agent	N.A.	Investigative	[4]
L-lysine	DMOD5CK	Discovery agent	N.A.	Investigative	[4]
L-serine	DM6WPIS	Pulmonary tuberculosis	1B10.Z	Investigative	[4]

Drug(s) Targeting Extracellular calcium-sensing receptor (CASR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cinacalcet	DMCX0K3	Hyperparathyroidism	5A51	Approved	[5]
Etelcalcetide	DMHP9BL	Secondary hyperparathyroidism	5A51.1	Approved	[6]
Encaleret	DMQSPFS	Autosomal dominant hypocalcemia	5A50.0Y	Phase 3	[7]
ASP7991	DM3TN1A	Hyperparathyroidism	5A51	Phase 2	[8]
MK-5442	DMHTIGU	Osteoporosis	FB83.0	Phase 2	[9]
ATF-936	DMWGKHZ	Osteoporosis	FB83.0	Phase 1	[10]
AXT-914	DM7ZU3B	Osteoporosis	FB83.0	Phase 1	[11]
R-568	DM5NWPD	N. A.	N. A.	Discontinued in Phase 2	[12]
Ronacaleret	DM10ZJP	Osteoporosis	FB83.0	Discontinued in Phase 2	[13]
NPS-2143	DMQPXLF	Osteoporosis	FB83.0	Discontinued in Phase 2	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Extracellular calcium-sensing receptor (CASR)	TTBUYHA	CASR_HUMAN	Modulator (allosteric modulator)	[2]
G-protein coupled receptor GPCR33 (GPRC6A)	TTI1PRE	GPC6A_HUMAN	Modulator (allosteric modulator)	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 719).
• [2] N2-benzyl-N1-(1-(1-naphthyl)ethyl)-3-phenylpropane-1,2-diamines and conformationally restrained indole analogues: development of calindol as a new calcimimetic acting at the calcium sensing receptor.Bioorg Med Chem Lett. 2004 Jun 21;14(12):3345-9.
• [3] Molecular determinants of non-competitive antagonist binding to the mouse GPRC6A receptor. Cell Calcium. 2009 Nov-Dec;46(5-6):323-32.
• [4] Deorphanization of GPRC6A: a promiscuous L-alpha-amino acid receptor with preference for basic amino acids. Mol Pharmacol. 2005 Mar;67(3):589-97.
• [5] Clinical pipeline report, company report or official report of Amgen (2009).
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [7] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035616)
• [9] Antagonist for calcium-sensing receptor. JTT-305/MK-5442. Clin Calcium. 2011 Jan;21(1):89-93.
• [10] ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans. Bone. 2011 Aug;49(2):233-41.
• [11] AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women. Bone. 2014 Jul;64:204-10.
• [12] Mixed-effects modeling of the pharmacodynamic response to the calcimimetic agent R-568. Clin Pharmacol Ther. 1999 Jan;65(1):40-9.
• [13] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [14] Calcium-sensing receptor antagonist (calcilytic) NPS 2143 specifically blocks the increased secretion of endogenous Abeta42 prompted by exogenous fibrillary or soluble Abeta25-35 in human cortical astrocytes and neurons-therapeutic relevance to Alzheimer's disease. Biochim Biophys Acta. 2013 Oct;1832(10):1634-52.